Gefapixant Safe, But Failed to Reduce Cough Frequency

Gefapixant Safe, But Failed to Reduce Cough Frequency

298506

Gefapixant Safe, But Failed to Reduce Cough Frequency

Gefapixant (MK-7264), an investigational cough suppressant, was safe and well-tolerated by patients with idiopathic pulmonary fibrosis (IPF), but did not significantly reduce chronic coughing, according to data from a Phase 2 clinical trial. Results from this trial were shared in the study, “Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial,” published in the journal Pulmonary Therapy. A chronic cough often accompanies IPF. Although…

You must be logged in to read/download the full post.